Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 6,400 shares, an increase of 30.6% from the February 28th total of 4,900 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 43,900 shares, the days-to-cover ratio is presently 0.1 days.

Emmaus Life Sciences Price Performance

OTCMKTS:EMMA traded down $0.00 during trading hours on Tuesday, hitting $0.02. The company had a trading volume of 11,093 shares, compared to its average volume of 46,039. The stock has a 50-day moving average price of $0.02 and a 200 day moving average price of $0.02. The company has a market capitalization of $1.09 million, a PE ratio of -0.19 and a beta of 6.47. Emmaus Life Sciences has a 52 week low of $0.00 and a 52 week high of $0.12.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.